期刊文献+

多西他赛纳米制剂的研究进展

Research advances in nanoformulations of docetaxel
下载PDF
导出
摘要 多西他赛是一种紫杉烷类抗肿瘤药物,对多种癌症有良好临床疗效,但其本身及上市制剂溶媒可引发严重的不良反应,使临床应用受到影响。纳米制剂在缓释药物、延长药效、降低毒性、提高难溶性药物的生物利用度等方面表现出良好的应用前景,成为国内外研究的热点。本文综述了近年来关于多西他赛纳米制剂的研究,对其研发和应用前景进行展望,以期为多西他赛新型纳米制剂的研究和应用提供参考。 Docetaxel,one of the taxoid antitumor drugs,has good clinical effects on many kinds of cancer.However,due to the side effects caused by docetaxel itself and its solvent,its application is seriously restricted clinically.As nanoformulations have shown good perspective in terms of sustained drug release,prolonged drug efficacy,reduced toxicity and improved bio-availability of insoluble drugs,they are now a hot research topic both at home and abroad.This paper gives a comprehensive re-view on the current literature of nanoformulations of docetaxel as well as a perspective on future development and application,so as to provide reference for the research and development of new nanoformulations of docetaxel.
作者 许幼发 程丹 傅志勤 陈建明 XU YouFa;CHENG Dan;FU ZhiQin;CHEN JianMing(Teaching Office of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China;Teaching Office of Pharmaceutics,School of Pharmacy,Second Military Medical University,Shanghai 200433,China)
出处 《药学服务与研究》 CAS 2018年第2期81-86,共6页 Pharmaceutical Care and Research
关键词 多西他赛 抗肿瘤药物 纳米制剂 综述 docetaxel antitumor drug nanoformulation review
  • 相关文献

参考文献2

二级参考文献28

  • 1Lukyanov A N, Torchilin V P. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble dmgs[J]. Adv Drag Deliv Rev, 2004, 56(9) ~ 1273.
  • 2Uchegbu I, Jeoma F, Florence A. Nonionic surfactant vesicles (niosomes) : physical and pharmaceutical chemistry [ J]. Adv Coll lnt Sci, 1995, 58(1)i 1.
  • 3Uchegbu I F, Vyas S P. Nonionic surfactant based vesicles(nio-somes) in drug delivery[J]. Int J Pharm, 1998, 172(98) : 33.
  • 4Rogerson A, Cummings J, Willmott N. The distribution of doxo- rubicin in mice following administration in niosomes[ J]. J Pharm PhaImacol, 1988, 40(5) : 337.
  • 5Mei L, Zhang Z, Zhao L, et al. Pharmaceutical nanotechnology for oral delivery of anticancer drugs [ J ]. Adv Drug Deliv Rev, 2013, 65(6) : 880.
  • 6Zhang Z P, Mei L, Feng S S. Vitamin E d-a-tocopheryl polyeth- ylene glycol 1000 succinate-based nanomedicine[J]. Nanomedi- cine(Lond), 2012, 7(1): 1645.
  • 7Jakate A S, Einhaus C M, De Anglis, et al. Preparation, char- acterization, and preliminary application of fibrinogen-coated ol- ive oil droplets for the targeted delivery of docetaxel to solid ma- lignancies[J]. Cancer Res, 2003, 63(21 ) : 7314.
  • 8Mahmound E, Marie-~ve P, Nicolas B, et al. Solubilization of docetaxel in poly ( ethyleneoxide ) -block-poly ( butylene /styrene oxide) micelles I J 1. Biomacrmnolecules, 2007, 8 (7) : 2250.
  • 9Shepherd F A, Rodrigues P J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer[ Jl- N Engl J Med, 2005, 353(2) : 2589.
  • 10Thatcher N, Change A, Pafikh P, et al. Gefitinib plus best sup- portive care in previously treated patients with rofraetoIy advanced non-small-cell lung cancer: results from a randomized, placebo- controlled, multicentre study( Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005, 366(9496): 527.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部